Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR442970 in Moderate to Severe Hidradenitis Suppurativa
2022-502370-17-00Phase 2Completed
- Sponsor
- Sanofi
- Start
- Aug 2023
- Modality
- Nanobodies (VHH) → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 15
01
Overview
Phase 2, randomised, double-blind trial in hidradenitis suppurativa (HS) comparing SAR442970 with Placebo (2 arms). Primary endpoint: Percentage of biologic and small molecule immunosuppressive naïve participants achieving HiSCR50. Started Aug 2023; status: completed.
02
Drugs
brivekimig
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2022-502370-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-502370-17-00.